A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

Campbell, Ciarán; McCormack, Mark; Patel, S.; P. Stapleton, Caragh; Reddy Bobbili, Dheeraj; Krause, Roland; Depondt, Chantal; J. Sills, Graeme; P.C. Koeleman, Bobby; Striano, Pasquale; Zara, Federico; W. Sander, Josemir; Lerche, Holger; S. Kunz, Wolfram; Stefánsson, Kāri; Stefánsson, Hreinn; P. Doherty, Colin; L. Heinzen, Erin; E. Scheffer, Ingrid; B. Goldstein, David; J. O’Brien, Terence; Cotter, David; F. Berkovic, Samuel; M. Sisodiya, Sanjay; Delanty, Norman; L. Cavalleri, Gianpiero

doi:10.1111/epi.17228

Public

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

Published in Epilepsia • Mar 17, 2022

Authors:

Ciarán Campbell

Mark McCormack

S. Patel

Abstract

OBJECTIVE: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%-20% of people treated with LEV report psychiatric side-effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine t...

Subject

Levetiracetam

Psychiatry

Schizophrenia (object-oriented programming)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!